Astellas Pharma Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Astellas Pharma stock has a consensus rating of "Buy" and an average price target of ¥2,385. The average 1-year stock price forecast is 11.33% higher than the current stock price, while the lowest is ¥1,600 (-25.30%) and the highest is ¥2,950 (+37.72%).

Price Target: ¥2,385 (+11.33%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	¥1,600	¥2,385	¥2,400	¥2,950
Change	-25.30%	+11.33%	+12.04%	+37.72%

Analyst Ratings

The average analyst rating for Astellas Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '26	Mar '26	Apr '26	May '26	Jun '26	Jul '26
Strong Buy	3	4	4	4	4	4
Buy	0	0	0	0	0	0
Hold	10	9	9	8	8	8
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	14	14	14	13	13	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Miki Sogi Bernstein	Bernstein	Hold Maintains ¥2,200	Hold	Maintains	¥2,200	+2.71%	Jul 7, 2026
Unknown Analyst J.P. Morgan No rating	J.P. Morgan	Hold Maintains ¥2,300	Hold	Maintains	¥2,300	+7.38%	Jun 29, 2026
Unknown Analyst Bank of America Securities No rating	Bank of America Securities	Buy Maintains ¥2,700	Buy	Maintains	¥2,700	+26.05%	Jun 5, 2026
Unknown Analyst Macquarie No rating	Macquarie	Buy Maintains ¥2,800 → ¥2,600	Buy	Maintains	¥2,800 → ¥2,600	+21.38%	May 28, 2026
Unknown Analyst UBS No rating	UBS	Hold Maintains ¥2,600 → ¥2,400	Hold	Maintains	¥2,600 → ¥2,400	+12.04%	May 25, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

2.25T

from 2.14T

5.18%

from 2.14T

Revenue Next Year

2.07T

from 2.25T

-7.93%

from 2.25T

EPS This Year

n/a

from -

EPS Next Year

n/a

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025	Mar 31, 2026	Mar 31, 2027
Revenue	1.30T	1.52T	1.60T	1.91T	2.14T	2.25T
Revenue Growth	3.73%	17.16%	5.60%	19.25%	11.87%	5.18%
Gross Profit	1.04T	1.23T	1.31T	1.56T	1.73T	1.81T
Gross Margin	80.48%	81.01%	81.76%	81.74%	80.91%	80.42%
Operating Income	218.15B	231.65B	124.61B	263.54B	439.28B	457.11B
Net Income	124.09B	98.71B	17.05B	50.75B	291.54B	344.59B
Dividend / Share	50.00	60.00	70.00	74.00	78.00	80.46
Dividend Growth	-	20.00%	16.67%	5.71%	5.41%	3.16%
Free Cash Flow	174.91B	202.24B	134.67B	125.26B	426.79B	421.32B
No. Analysts	-	-	-	-	-	12

Financial currency is JPY.

Revenue Forecast

Revenue	2027	2028	2029
High	2.3T
Avg	2.3T
Low	2.2T

Revenue Growth

Revenue Growth	2027	2028	2029
High	9.5%
Avg	5.2%
Low	2.8%

EPS Forecast

EPS	2027	2028	2029
High	-
Avg	-
Low	-

EPS Growth

EPS Growth	2028	2029
High	-
Avg	-
Low	-